Seven Deaths in September
On the morning of September 29, 1982, a twelve-year-old girl named Mary Kellerman stayed home from school with a runny nose and a headache. Her parents told her to take a couple of Tylenol and rest. Her father heard her walk into the bathroom, heard the door close, heard something drop. He called her name twice. No answer. When he opened the door, Mary was on the floor in her pajamas, unconscious. She was pronounced dead at a Chicago-area hospital from what no one could yet explain.
A few hours later, twenty-seven-year-old postal worker Adam Janus took two Extra-Strength Tylenol for a headache at his home in a nearby suburb. He collapsed almost instantly. His younger brother and sister-in-law, grief-stricken at his wake, reached for the same bottle. They were the next to die. By the end of September 30, seven people in the Chicago metropolitan area had been killed by cyanide-laced capsules placed inside Tylenol bottles on pharmacy shelves — a mother of four with a week-old infant, a flight attendant found days later with an open bottle still on her bathroom counter. The murderer was never caught.
What happened next became the most studied crisis response in the history of American business. Johnson & Johnson — then a $5.4 billion conglomerate already ninety-six years old, its name synonymous with the soft, powdery innocence of the nursery — pulled thirty-one million bottles of Tylenol from store shelves at a cost exceeding $100 million. It introduced tamper-proof packaging that would become an industry standard, then a federal requirement. CEO James Burke went on 60 Minutes and The Donahue Show, projecting transparency at a moment when corporate instinct overwhelmingly favored silence. Tylenol's market share, which had collapsed from 37% to 7% overnight, clawed back to 30% within a year. The product survived. The brand survived. The company's reputation didn't just survive — it was transformed into something approaching secular sainthood.
For four decades, the Tylenol crisis has been taught at every business school as the canonical case study in values-driven leadership. And for four decades, Johnson & Johnson has traded on that reputation — the company that put consumers first, that lived its Credo, that chose principle over profit when the world was watching.
The question that defines Johnson & Johnson in the twenty-first century is whether the Tylenol crisis revealed the company's character or merely established a mythology powerful enough to survive the accumulation of contrary evidence.
By the Numbers
Johnson & Johnson at a Glance (FY 2024)
$88.8BTotal revenue (fiscal year 2024)
~$380BMarket capitalization (mid-2025)
~94,000Employees worldwide (post-Kenvue)
$55.4BInnovative Medicine segment revenue
$33.4BMedTech segment revenue
62Consecutive years of dividend increases
8Total CEOs in 139-year history
$9B+Proposed talc settlement (rejected by courts, 2025)
Three Brothers and a Bandage
The founding mythology is simpler than most. In January 1886 — the same year Coca-Cola was mixed in an Atlanta pharmacy and Karl Benz patented the automobile — three brothers named Johnson incorporated a company in New Brunswick, New Jersey, to manufacture sterile surgical dressings. Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson were not scientists or physicians. They were businessmen who had attended a lecture by the British antiseptic surgery pioneer Joseph Lister and recognized that his ideas about germs and sterile procedure, still controversial in American medicine, represented an enormous commercial opportunity. The gap between what science knew and what surgical practice did was, quite literally, killing people. The Johnsons proposed to fill it with a product.
Their first factory, a former wallpaper plant on the banks of the Raritan River, began producing gauze bandages and surgical dressings wrapped in individual packages — a radical concept when most hospitals still made their own from bulk cotton that was neither sterile nor standardized. The company grew quickly through a combination of genuine innovation (the development of mass-produced sterile sutures, the publication of a widely distributed guide called Modern Methods of Antiseptic Wound Treatment) and relentless commercial hustle. Edward Mead Johnson left in 1897 to found what became Mead Johnson & Company. Robert Wood Johnson I, the eldest and the driving force, died in 1910. But the entity he created survived the transition because the family's second generation proved even more consequential than the first.
Robert Wood Johnson II — known within the company as "the General" for his World War II service — took the company public in 1944 and, more importantly, authored the document that would become Johnson & Johnson's most durable competitive asset: the Credo.
Robert Wood Johnson II's 1943 stakeholder framework
Written a year before J&J's IPO, the Credo was a single-page statement of corporate responsibility that listed the company's obligations in a specific, deliberate order: first to doctors, nurses, patients, and mothers who use its products; second to its employees; third to the communities in which it operates; and last — explicitly, pointedly last — to its stockholders. "When we operate according to these principles," Johnson wrote, "the stockholders should realize a fair return."
This was radical for 1943. It remains radical now. The Credo's hierarchy inverted the prevailing logic of shareholder primacy decades before anyone called it "stakeholder capitalism." It gave the company a rhetorical framework — and, its defenders argue, an operational discipline — that other firms spent the next eighty years trying to copy without ever quite reproducing the original.
The General ran J&J for nearly three decades, transforming it from a surgical supply company into a diversified healthcare conglomerate. He pioneered what would become the company's defining structural innovation: extreme decentralization. Rather than consolidating acquired businesses into a single operating unit, Johnson let each subsidiary operate with extraordinary autonomy — its own president, its own P&L, its own culture, its own relationship with its market. The parent company provided capital, strategic guidance, and the Credo. Everything else was local.
This was not philosophical whimsy. The General believed that healthcare markets were too diverse, too local, and too technically specialized for centralized management to serve them well. A surgeon in São Paulo had different needs than a pediatrician in New Jersey, and both had different needs than a consumer mother buying baby shampoo. The decentralized model allowed J&J to compete simultaneously in pharmaceuticals, medical devices, and consumer health — three industries with fundamentally different innovation cycles, regulatory regimes, and distribution channels — without forcing any of them into a single operating template.
By the time the General died in 1968, Johnson & Johnson operated over a hundred subsidiary companies across dozens of countries. The architecture he built would outlast him by more than half a century, surviving multiple CEO transitions, industry upheavals, and — eventually — a series of crises that tested whether the Credo was a living document or a decorative plaque.
The Credo as Operating System
What made the Credo more than corporate wallpaper was an institutional mechanism that few outsiders understood. Beginning in the 1970s under CEO James Burke — the same Burke who would navigate the Tylenol crisis — J&J conducted what it called "Credo Challenge" sessions. Burke would gather groups of managers and force them to debate the Credo line by line: Did they believe it? Did it still apply? Were there situations where following it would damage the business? If managers couldn't defend the Credo, Burke said, they should take it off the wall and stop pretending.
If we aren't going to live by the Credo, let's tear it off the wall.
This was not empty theater. The Credo Challenge sessions, which ran across the company's global operations for years, served a dual function. They forced genuine engagement with the company's values at a time when most corporate mission statements were produced by PR departments and forgotten by Tuesday. And they created a shared vocabulary — a common reference framework that allowed managers in J&J's wildly decentralized structure to make decisions aligned with corporate intent without requiring centralized approval. The Credo was, in effect, a coordination mechanism disguised as a moral statement.
When the Tylenol crisis hit in 1982, Burke's response was instinctive precisely because the Credo had already been stress-tested. There was no debate about whether to pull the product. The Credo said the first responsibility was to patients and consumers. Pull the product. The Harvard Business School case study on Johnson & Johnson's culture, first published in 1983, captured this dynamic: the company's systems, structures, and procedures were designed to reflect and promote a culture in which the right decision was also the obvious one.
The Tylenol response earned J&J something that money cannot buy and advertising cannot fabricate: the benefit of the doubt. For decades afterward, when regulators questioned a product, when lawsuits were filed, when quality problems emerged, the public and the press extended Johnson & Johnson a presumption of good faith that no other pharmaceutical company enjoyed. The Credo was the shield. The Tylenol response was the proof.
The question is what happens when the shield is used to deflect accountability rather than inspire it.
The Pharma Machine Behind the Baby Powder
For most of its public life, Johnson & Johnson was perceived as a consumer products company — baby shampoo, Band-Aids, Tylenol, the comforting red script logo on products in every American medicine cabinet. This perception, while commercially useful, obscured the reality of where the money actually came from.
By the 2000s, J&J's pharmaceutical division — anchored by its subsidiary Janssen Pharmaceuticals, originally a Belgian firm acquired in 1961 — had become the engine of the enterprise. The consumer business was large, stable, and massively profitable, but it grew slowly. The medical devices business was cyclical and competitive. Pharma was where the margins lived.
The acquisition of Janssen was itself a masterclass in the J&J playbook. Paul Janssen, the Belgian physician-chemist who founded the company, had personally developed or supervised the development of more than eighty drugs over his career — an output so prolific it bordered on the implausible. J&J bought Janssen in 1961 but, crucially, let Paul Janssen keep running it. The decentralized model wasn't just organizational theory; it was how you retained a genius who might otherwise leave. Janssen Pharmaceuticals developed drugs including haloperidol (an antipsychotic), fentanyl (originally an anesthetic, later an agent of catastrophe), loperamide (Imodium), and risperidone (Risperdal). Each of these became a blockbuster. Several became controversies.
The pharmaceutical transformation accelerated through the 1990s and 2000s. J&J acquired biotech companies — Centocor in 1999 for $4.9 billion, Crucell in 2011 for $2.4 billion, Actelion in 2017 for $30 billion — building capabilities in immunology, infectious disease, and pulmonary hypertension. The crown jewel that emerged was Stelara, a monoclonal antibody for psoriasis and Crohn's disease that generated roughly $10 billion in peak annual sales, making it one of the best-selling drugs in the world.
But the pharmaceutical business also brought pharmaceutical liabilities. Risperdal, the blockbuster antipsychotic, became the subject of a Department of Justice investigation and a $2.2 billion settlement in 2013 over allegations that J&J had illegally marketed the drug for uses not approved by the FDA, including to elderly dementia patients and children. Internal documents suggested that executives had known the off-label marketing was occurring and had done little to stop it. The company denied wrongdoing as part of the settlement.
The conduct at issue in this case jeopardized the health and safety of patients and violated the public trust.
The Risperdal settlement was large but, for J&J, financially manageable — a cost of doing business in an industry where the penalties for misconduct were routinely dwarfed by the revenues the misconduct generated. It was a pattern that would repeat.
The Architecture of Decentralization
To understand how Johnson & Johnson could simultaneously be the company that pulled Tylenol from shelves at enormous cost and the company that marketed Risperdal to children, you have to understand the structure.
At its peak, J&J operated more than 250 subsidiary companies across 60 countries, selling products in over 175 nations. Each subsidiary had its own president, its own management team, its own board of directors (often including J&J corporate officers), and its own P&L. The parent company in New Brunswick set strategic direction, allocated capital, and enforced the Credo. But day-to-day operations — including, critically, marketing decisions, quality control processes, and regulatory strategy — were handled locally.
This created extraordinary advantages. The decentralized model allowed J&J to acquire companies without destroying them. It attracted entrepreneurial talent that would never tolerate a centralized bureaucracy. It enabled speed in local markets — a J&J subsidiary in Brazil could respond to Brazilian regulatory changes without waiting for New Jersey to issue guidance. And it created a portfolio effect: when one subsidiary struggled, others thrived, smoothing the conglomerate's overall performance.
The disadvantages were the mirror image. Decentralization made it harder to enforce consistent quality standards across hundreds of facilities. It created information silos where problems in one subsidiary were invisible to others. And it generated a convenient structure for deniability: when a subsidiary did something wrong, the parent company could plausibly claim it hadn't known. The same autonomy that enabled innovation also enabled misconduct to persist in the shadows of the org chart.
Between 2009 and 2011, J&J's consumer subsidiary McNeil Consumer Healthcare — the makers of Tylenol — executed a series of product recalls involving children's Tylenol, Motrin, Zyrtec, and Benadryl. The recalls were triggered by quality control failures at a manufacturing plant in Fort Washington, Pennsylvania, including reports of a musty odor caused by a chemical used to treat wooden pallets. In one particularly embarrassing episode, J&J hired contractors to quietly buy back defective Motrin from store shelves without issuing a formal recall — a maneuver later revealed by congressional investigators. The FDA issued a consent decree requiring oversight of McNeil's manufacturing operations.
For the company that had made its name through its Tylenol recall, the irony was devastating. The product that had built the brand was now the product that was eroding it.
Powder, Asbestos, and the Long Fuse
If the Risperdal settlement was financially manageable and the McNeil recalls were reputationally embarrassing, the baby powder litigation was existential — not because it threatened J&J's solvency, but because it threatened the one thing that had always been the company's ultimate asset: trust.
Johnson's Baby Powder, the talc-based product in its iconic white bottle, had been a fixture of American domestic life since the late nineteenth century. Generations of mothers dusted their infants with it. Women used it as a personal hygiene product. The powder was so closely associated with J&J's identity that it functioned less as a product and more as a symbol — of purity, of care, of the tender bond between parent and child.
The problem was that talc, the mineral from which the powder was made, is often found in geological formations alongside asbestos, a known carcinogen. Epidemiological research dating back decades had suggested links between talc use in the genital area and ovarian cancer. The danger of asbestos contamination in talc had been noted in scientific literature as early as the 1920s.
The growth and popularity of J&J baby powder grew as data about the dangers grew. They were almost alongside each other.
Investigative journalism — most notably a series of Reuters reports beginning in 2018 — revealed internal J&J documents showing that the company had known for decades about the presence of trace asbestos in some of its talc supplies. Internal memos showed that J&J executives had discussed the problem, debated how to respond, and continued selling the product. The company maintained that its products were safe and that the science supporting a link between talc and cancer was flawed.
In October 2019, the FDA detected chrysotile asbestos in a bottle of Johnson's Baby Powder purchased from an online retailer. J&J recalled 33,000 bottles. In 2020, the company discontinued talc-based baby powder sales in the United States, replacing talc with cornstarch while continuing to sell the talc formulation internationally. It attributed the U.S. discontinuation to "slumping sales fueled by misinformation."
By then, approximately 38,000 lawsuits had been filed against the company by individuals — overwhelmingly women — alleging that Johnson's Baby Powder had caused their cancer. Advocacy groups noted that J&J had specifically marketed the product to Black women. Internal marketing documents confirmed targeted campaigns.
What followed was a legal strategy that, regardless of its legality, struck many observers as a betrayal of everything the Credo purported to stand for.
The Texas Two-Step
In October 2021, J&J executed a corporate maneuver that became known as the "Texas Two-Step." The company created a new subsidiary in Texas, transferred all of its talc-related liabilities to that subsidiary, then immediately moved the subsidiary to North Carolina and had it file for bankruptcy. The strategy was designed to resolve tens of thousands of cancer lawsuits through a single bankruptcy proceeding rather than facing them one by one in courts across the country.
The logic, from J&J's perspective, was straightforward: the litigation was sprawling, expensive, and unpredictable. Jury verdicts had been enormous — a Missouri court awarded $4.69 billion to twenty-two women in 2018, later reduced but still staggering. A global settlement through bankruptcy, J&J argued, would provide certainty and fair compensation to all claimants rather than enriching a few who happened to draw sympathetic juries while others received nothing.
The logic, from the plaintiffs' perspective, was equally straightforward: a $400+ billion company was using a bankruptcy loophole to shield itself from accountability for selling a cancer-causing product to women and children for decades. The subsidiary that filed for bankruptcy, LTL Management, had essentially no assets of its own. It was a shell designed to contain liability, not to operate a business.
Federal courts ultimately rejected J&J's bankruptcy strategy — not once, but multiple times. In January 2025, a federal judge in Texas rejected J&J's proposed $9 billion settlement plan. The Third Circuit Court of Appeals and the Supreme Court had previously declined to revive earlier versions of the maneuver. J&J's legal defense, as journalist Gardiner Harris put it in his 2025 book, was "beginning to crumble."
The talc saga revealed something uncomfortable about the relationship between the Credo and the corporation. The Credo said the first responsibility was to patients and consumers. The Texas Two-Step said the first priority was managing litigation exposure. Both could not be true simultaneously.
The Kenvue Separation
Against the backdrop of the talc litigation, J&J's leadership made the most consequential structural decision in the company's 135-year history: it would separate its consumer health business entirely.
In November 2021, CEO Joaquin Duato — who had assumed the role from Alex Gorsky just months earlier — announced that J&J would spin off its consumer health division into a standalone public company. The timing was conspicuous. The consumer business, which included Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, and, yes, Johnson's Baby Powder, carried both the company's most beloved brands and its most toxic liabilities. The separation would leave "New J&J" as a focused pharmaceutical and medical technology company. The consumer business and its associated litigation exposure would belong to someone else.
Timeline of J&J's largest restructuring
Nov 2021J&J announces plan to separate its consumer health business
Jan 2023Kenvue Inc. files S-1 registration statement with the SEC
May 2023Kenvue IPO at $22/share, raising $3.8 billion — largest U.S. IPO since Rivian (2021)
Aug 2023J&J offers exchange of up to 1.53 billion Kenvue shares for J&J stock at ~7.5% premium
May 2024J&J completes debt-for-equity exchange of final 182 million Kenvue shares
2024Kenvue trades as fully independent company under KVUE on NYSE
The IPO of Kenvue Inc. on May 4, 2023, valued the consumer business at roughly $50 billion on its first day of trading, with shares jumping 22% above the $22 offering price. J&J initially retained a 90.9% stake, then systematically divested it through an exchange offer in August 2023 (offering shareholders $107.53 of Kenvue stock for every $100 of J&J stock tendered) and a final debt-for-equity exchange in May 2024. Kenvue CEO Thibaut Mongon, the former J&J consumer health chief, declared the separation a move made "from a position of strength." Kenvue had posted $14.95 billion in sales and $1.46 billion in net income for fiscal 2022.
The separation was strategically coherent: consumer health products were growing slowly, carried lower margins than pharmaceuticals, and faced intense private-label competition. Pharmaceutical and medtech businesses demanded massive R&D investment, operated under different regulatory regimes, and served entirely different customers. Bundling them together created a conglomerate discount that Wall Street increasingly penalized.
But the separation also had a less charitable reading. J&J was jettisoning the division most associated with the talc lawsuits — and with the consumer-facing trust that the Credo had been built to protect — while retaining the higher-margin pharmaceutical and device businesses. The talc liabilities remained with the J&J parent entity (and its controversial bankruptcy subsidiary), but the emotional and reputational center of the Johnson & Johnson brand — the baby products, the Band-Aids, the Tylenol — now belonged to Kenvue.
What remained was, financially, a much stronger company. But it was also a different company — one whose identity could no longer rest on the nursery-soft imagery that had defined it for over a century.
Duato and the New J&J
Joaquin Duato became J&J's eighth CEO in January 2022, and its first not born in the United States. Born in Valencia, Spain, Duato had joined J&J after initially being rejected by the company following graduate school — he didn't make it past the first round of interviews. He found his way back, spent thirty-four years rotating through geographies, sectors, and functions, and rose to run the pharmaceutical division before succeeding Alex Gorsky.
Gorsky, a West Point graduate and Army veteran who led J&J from 2012 to 2022, had steered the company through the Risperdal settlement, the McNeil consent decree, the talc escalation, and the COVID-19 vaccine development — a decade defined by simultaneous reputational erosion and financial growth. Gorsky was a polished corporate leader, comfortable on CNBC and at Davos, who projected calm competence while the legal and regulatory ground shifted beneath him. His decade produced strong financial returns and a portfolio of acquisitions (Actelion for $30 billion, Auris Health for $3.4 billion, Momenta Pharmaceuticals for $6.5 billion) that reshaped J&J's pipeline. It also produced the Texas Two-Step.
Duato inherited all of it. His stated priorities were dual: remain true to the mission of addressing difficult-to-treat diseases and maintain the principle-based, people-based culture that had always been J&J's differentiator. In one of few interviews since becoming CEO, at Fortune's CEO Initiative conference in October 2023, Duato spoke with evident pride about J&J's low attrition rate — well below industry averages — and the company's internal career mobility. "Johnson & Johnson has its internal job market," he said.
In our 130 years of history, we have had only eight CEOs. And I am the first one who is not born in the U.S. And I'm proud to represent that.
Duato's strategic agenda was clear: focus the post-Kenvue company on two growth engines. The Innovative Medicine segment (formerly Janssen) would drive pipeline development in oncology, immunology, neuroscience, and cardiovascular disease. The MedTech segment would push into surgical robotics, digital surgery, and interventional solutions. Both segments required massive R&D spending — J&J invested approximately $15.1 billion in R&D in fiscal 2024 — and both offered margins that the consumer business could never match.
The bet was that J&J could become the world's preeminent healthcare innovation company while shedding the conglomerate complexity that had defined its first 135 years. But the bet also assumed that the company's reputation — the trust capital accumulated over more than a century — would survive the separation from the consumer brands that had built it.
The Vaccine That Almost Wasn't
J&J's COVID-19 vaccine, developed by its Janssen subsidiary using an adenoviral vector platform, was authorized by the FDA for emergency use on February 27, 2021 — a genuine scientific achievement produced at extraordinary speed. It was the only single-dose COVID vaccine authorized in the United States, which made it especially valuable for hard-to-reach populations, military deployments, and developing countries where cold-chain storage for the mRNA vaccines was impractical.
It was also a commercial and reputational catastrophe. In April 2021, the FDA and CDC recommended pausing administration of the Janssen vaccine after six cases of a rare blood-clotting disorder were identified among nearly seven million doses administered. The pause lasted eleven days. But the damage to public confidence was immediate and, as it turned out, irreversible. Even after the pause was lifted, uptake cratered. The vaccine that was supposed to be J&J's contribution to ending the pandemic became instead a cautionary tale about the fragility of public trust in pharmaceutical products.
Subsequent data showed the Janssen vaccine was significantly less effective than the Pfizer and Moderna mRNA vaccines against emerging variants. The CDC eventually downgraded its recommendation, preferring mRNA vaccines. By June 2023, the Janssen vaccine's emergency use authorization was effectively withdrawn as remaining stocks expired. J&J had invested heavily in manufacturing capacity — including a partnership with Merck, brokered by the Biden administration, that was itself unprecedented — and had pledged to sell the vaccine on a not-for-profit basis during the pandemic. The financial loss was manageable. The reputational loss was not.
The vaccine episode crystallized a tension that had been building for decades. J&J's most powerful asset was public trust — the belief that Johnson & Johnson products were safe, that the company cared more about patients than profits, that the Credo meant something. But each successive controversy — Risperdal, the recalls, the talc litigation, the Texas Two-Step, the vaccine debacle — drew down that trust account without any corresponding deposits. The Tylenol response had been the ultimate deposit. Nothing since had matched it.
The Golden Era, If You Squint
Duato has called the current moment "the golden era for health innovation," and on the evidence of J&J's pipeline, he is not wrong. The company's Innovative Medicine segment posted $55.4 billion in revenue in fiscal 2024, driven by a portfolio that spans oncology (Darzalex for multiple myeloma, Carvykti for CAR-T cell therapy, Rybrevant and Lazcluze for lung cancer), immunology (Tremfya for psoriasis and ulcerative colitis, positioned as the successor to the $10 billion Stelara franchise), and neuroscience (Spravato for treatment-resistant depression, the first truly novel antidepressant mechanism in decades).
The MedTech segment, at $33.4 billion in fiscal 2024 revenue, was anchored by orthopedics (DePuy Synthes hip and knee replacements), surgery (Ethicon sutures and wound closure, the MONARCH robotic-assisted bronchoscopy platform), and cardiovascular intervention (intravascular lithotripsy from the 2023 Shockwave Medical acquisition, reportedly valued at approximately $13.1 billion). J&J was betting that robotics and digital surgery would transform the MedTech business from a commodity hardware business into a recurring-revenue platform business — the same transformation that had enriched Intuitive Surgical in general surgery.
💊
Key Pipeline Assets (2024–2025)
J&J's pharmaceutical and MedTech growth drivers
| Product | Indication | Segment | Status |
|---|
| Darzalex (daratumumab) | Multiple myeloma | Innovative Medicine | Peak/mature blockbuster |
| Tremfya (guselkumab) | Psoriasis, UC, Crohn's | Innovative Medicine | Expanding indications |
| Carvykti (ciltacabtagene) | Multiple myeloma (CAR-T) | Innovative Medicine | |
The pipeline was genuinely impressive. But it faced a challenge that every pharmaceutical company must eventually reckon with: the Stelara patent cliff. Biosimilar competition to Stelara — which had generated roughly $21.4 billion in global sales at its peak — began eroding the franchise in 2025. Analysts estimated that the loss of Stelara exclusivity could eliminate $8–10 billion in annual revenue over the next several years. The new products needed to fill an enormous hole simply to maintain the status quo.
This was the essential tension of Duato's J&J: the company was simultaneously rich with innovation and vulnerable to patent cliffs, simultaneously respected for its science and distrusted for its legal maneuvering, simultaneously a leader in healthcare and a defendant in tens of thousands of cancer lawsuits. Every element of the bull case had its mirror-image bear case. The golden era and the crisis coexisted in the same building.
The Family, the Fortune, and the Foundation
No account of Johnson & Johnson is complete without the dynasty — not the corporate dynasty of CEOs, but the actual Johnson family, whose wealth, philanthropy, and dysfunction shaped the company and the nation in ways that extended far beyond the balance sheet.
Robert Wood Johnson II, the General, did not merely run J&J. He endowed the Robert Wood Johnson Foundation, which became the largest philanthropy focused exclusively on health in the United States, with assets that would grow to exceed $11 billion. He also, through his personal fortune and the foundation's influence, reshaped American healthcare policy for decades — funding research, advocating for public health infrastructure, and incubating ideas that eventually became government programs.
The third generation was more complicated. Robert Wood Johnson III (known as "Bobby") died young. His half-brother, J. Seward Johnson Sr., became the patriarch of a family whose internal feuds and scandals would fill two books —
Undue Influence by David Margolick, which chronicled the epic court battle over J. Seward Sr.'s will, and
Crazy Rich by Jerry Oppenheimer, which excavated the power, scandal, and tragedy that attended one of America's wealthiest clans. The Johnson family's relationship to the company they founded was, by the late twentieth century, more financial than operational — they were heirs and shareholders, not managers. But the family name remained on the building, on the products, and on the Credo.
The company's own institutional history is captured in
A Company That Cares, an illustrated centennial volume that tells the authorized version of the J&J story. For a more critical examination of the broader Gilded Age context in which the company emerged, Matthew Josephson's classic
The Robber Barons remains essential reading on the era's industrial consolidation.
A Compound Fracture in the Narrative
By mid-2025, Johnson & Johnson existed in a state of productive contradiction. Financially, the company had never been stronger in pure pharmaceutical terms. The Innovative Medicine segment was delivering blockbuster growth. The MedTech segment was investing in robotics and digital platforms that could transform surgical care. The Kenvue separation had unlocked value and clarified strategic focus. Revenue for fiscal 2024 reached $88.8 billion. The company had increased its dividend for sixty-two consecutive years — a record matched by fewer than a dozen American companies.
Reputationally, the picture was darker. Gardiner Harris's 2025 book
No More Tears: The Dark Secrets of Johnson & Johnson synthesized decades of reporting into a comprehensive indictment of J&J's business practices — from baby powder and asbestos to the marketing of opioids to the COVID vaccine's troubled rollout. The courts had rejected the company's bankruptcy strategy for resolving talc claims. Juries continued to hand down large verdicts. The company that had once been synonymous with trust was now, in the public imagination, increasingly synonymous with litigation.
The paradox was structural, not personal. J&J's leaders were not uniquely cynical. They operated within a system — the American pharmaceutical and medical device industry — where the incentives for aggressive marketing, liability management, and patent extension were baked into the business model. The Credo was real. The litigation was also real. The company's defenders argued that it was possible to simultaneously believe in the Credo and defend against lawsuits that the company genuinely believed were based on flawed science. The company's critics argued that the Texas Two-Step was the Credo turned inside out — that a company whose first obligation was to patients could not in good conscience use bankruptcy law to limit the compensation available to cancer victims.
Both arguments had merit. That was what made the story so uncomfortable.
On a warm day in New Brunswick, New Jersey, in the spring of 2025, the Credo still hung in the lobby of One Johnson & Johnson Plaza, where it had hung for decades. Outside, the Raritan River flowed past the same stretch of waterfront where three brothers had opened a bandage factory 139 years earlier. Inside, a $380 billion healthcare company was building CAR-T cell therapies and surgical robots while its lawyers argued in federal court about talcum powder and bankruptcy loopholes. The Credo said the first responsibility was to patients. The 10-K said the first risk factor was litigation. Somewhere between those two documents, Johnson & Johnson continued to exist.
